Industry Blog

Swine flu vaccines will cost €80m

THE SWINE flu pandemic will lead to one of the biggest vaccination programmes in the history of the State.

In the coming months, everyone in the country will be offered two doses of a vaccine which is still being developed by the pharmaceutical giants charged with bringing it to the market.

The vaccine the world is waiting for has not been developed yet but Dr Patrick Doorley, the HSE’s national director of population health, said he is certain there will be one. “First of all you have to identify the exact nature of the virus. That is why we did not have a vaccine before this happened. The big companies have all got the seeds now. We will have a vaccine. These companies are well used to making them,” he said.

In total, 7.7 million vaccines will be bought from three foreign pharmaceutical companies – GlaxoSmith-Kline, Baxter Healthcare and Allphar Services – at a combined cost of around €80 million.

There will be enough to immunise 3.85 million people, though the plan is to immunise everybody. There have been around 150 confirmed cases, but no deaths, to date in Ireland.

www.irishtimes.com

BBC reports pandemic flu service to go live

The National Flu Service is expected to go live later, giving thousands of swine flu sufferers access to drugs without needing to consult a GP.

The phone and website service, which will only cover England, is the first of its kind in the world.
It has been designed to relieve pressure on the NHS and will use a checklist to diagnose cases.
Pregnant women, people with health conditions and the under-ones will still all be referred to GPs.
The Department of Health has accepted that the service could be abused by people giving the answers they believe will give them access to anti-flu drugs.

But Chief Medical Officer Sir Liam Donaldson has said it is a price worth paying to help the NHS cope with its “biggest challenge in a generation”.
He told the BBC this week that the flu service might just be the first step in how the health service responds to a pandemic which has already claimed more than 700 lives across the world.
The death toll in the UK stands at 31, but that is likely to climb when the Department of Health in England releases its weekly update on Thursday.
Under contingency plans, non-emergency operations can be cancelled, while doctors can be moved around the health service to help flu hotspots cope.
The flu service does have some security checks in place. Those who are diagnosed with swine flu are given a voucher number for a flu friend to collect their drugs from a collection point.
Each person has their own unique number so the service will know if an individual is trying to get more than one dose of an anti-viral drug.
The flu friend will also have to present ID for the patient when they collect the drug.

It will be staffed by 1,500 call handlers to start with, although there is already capacity for 2,000 people in the network of call centres.

Demand

The free-phone number will only be operational during the day, but officials stressed that it will expand to meet the requirements of the pandemic.
Details of the website address and helpline number have yet to be released.
The launch of the service was announced last week after GPs and NHS Direct reported a dramatic rise in calls and consultations.
Every region of England is now seeing “exceptional” levels of activity with the exception of Yorkshire and the Humber.
And a poll of 1,500 NHS staff by the Health Service Journal and Nursing Times showed 14% did not think their organisation was coping successfully with the pressure.
The flu service is not covering the rest of the UK as Wales, Northern Ireland and Scotland have all experienced much less demand. They will be able to plug into it if and when they need to.
Dr Richard Vautrey, of the British Medical Association, which has helped to design the checklist being used by the flu service, said: “What we have to remember is that this is a unique situation.
“Some GP practices are receiving hundreds of calls a day and we have to prioritise so we can see the most seriously ill.
“It has been designed by doctors to pick up problems that need to be seen by someone with a medical background.
“So as long as the call handlers get the correct training we can be confident in this service.”

Flu vaccine available in October

There is no indication the A(H1N1) virus has mutated in Thailand and a vaccine is expected to be available in October, Public Health Minister Witthaya Kaewparadai said on Tuesday.

He was confident the swine flu outbreak could still be contained.

People with flu-like symptoms should visit hospitals quickly if the symptoms do not subside in two days, he said.

A vaccine against the A(H1N1) virus  should be available by October, and the government would initially import 12 million doses at a cost of about two million baht.

The Government Pharmaceutical Organisation and Silpakorn University would also jointly research a vaccine for use against the virus.

The Bureau of Epidemiology said that cases of human-to-human transmission could be expected to increase this month. People should take precautions by washing their hands regularly and wearing face masks in public places.

bangkokpost.com

Singapore’s Production Unexpectedly Gains on Pharmaceuticals.

Singapore’s industrial production unexpectedly increased in May as pharmaceutical companies boosted output.

Manufacturing, which accounts for about a quarter of Singapore’s economy, rose 2 percent from a year earlier following a revised 0.4 percent gain in April, the Economic Development Board said today. The median forecast in a Bloomberg News survey of seven economists was for a drop of 3 percent.

Singapore’s government said last month the nation may have “hit the bottom” of its deepest recession since independence in 1965. The narrowing of declines in the island’s exports and production has been helped by gains in pharmaceutical shipments, an industry economists describe as “volatile.”

“The pharmaceutical industry may have gotten a boost from demand for vaccines and other drugs amid the swine flu,” said Alvin Liew, an economist at Standard Chartered Bank in Singapore. “The broad picture shows that you can’t run away from the fact that electronics are still weak. I’m quite doubtful that this pace of recovery can be maintained.”

bloomberg.com

The swine flu threat

As media coverage dwindled, the swine flu threat faded from the minds of most Americans, despite warnings that we weren’t out of the woods yet. Many believed that the virus could return with a vengeance come flu season, but it appears that even those predictions may have been optimistic. On Wednesday, the WHO announced that 74 countries had reported 27,737 cases of H1N1, including 141 deaths. About half of the confirmed cases are in the U.S. In Australia, the number of reported cases has tripled in the last week, drawing the attention of the WHO as it evaluated the severity of the threat.

Pharmaceuticals in Focus

As perverse as it sounds, this latest development is good news for some. Pharmaceutical manufacturers have continued work on vaccines behind the scenes despite the apparent abatement of the threat. With the elevation of the pandemic alert level from 5 to 6, many pharmaceutical companies are likely to be flooded with requests (and funding) for vaccine development and testing. And as the likelihood of a worst-case scenario (a full-blown global outbreak) increases, so does the potential for a huge payday for vaccine manufacturers.

 

seekingalpha.com

Scottish woman is first Briton to die from swine flu

A patient suffering from swine flu has died in hospital in Scotland, becoming the first person outside the Americas to have been killed by the virus.

The Scottish government disclosed that the patient, thought to be from the Paisley area and one of 10 Scots in hospital with the H1N1 virus, had underlying health problems.

Last night the victim was locally identified as a 38-year-old woman from Glasgow, who had prematurely given birth to a baby in recent days. She had been in intensive care at the Royal Alexandra hospital in Paisley, where a large number of those infected with the H1N1 virus have been treated. Health officials said earlier today that nearly 500 people in Scotland had been diagnosed with the virus, with a majority in the Greater Glasgow and Clyde area.

The Scottish government released a statement shortly before 8pm tonight, stating: “With regret, we can confirm that one of the patients who had been in hospital and had been confirmed as suffering from the H1N1 virus, has died today. At the family’s request, to allow them time to come to terms with their loss, no further details will be released tonight.”

Nicola Sturgeon, the Scottish health secretary, said: “I’d like to express my condolences to the patient’s family and friends,” she said. “This is a tragedy for those concerned and they have my heartfelt sympathy. Tragic though today’s death is, I would like to emphasise that the vast majority of those who have H1N1 are suffering from relatively mild symptoms.”

Swine Flu

This week, pharmaceutical industry regulators and manufacturers moved quickly to address public health concerns regarding the outbreak and spread of the H1N1 virus infection (swine flu). The following is an overview of key developments.

RxResponse, a network partnership established by the Pharmaceutical Research and Manufacturers of America (PhRMA) and serves as a single-point of contact for the pharmaceutical supply system, declared it was on “Alert Status.” The announcement means that partnership members are closely monitoring developing information regarding influenza cases in the United States and will collaborate with other health agencies to ensure an efficient supply chain. “Americans need to know that the medicines they rely on will be available even in an emergency. RxResponse provided federal and state crisis managers with the critical information they need about the pharmaceutical supply chain to help communities affected by an emergency return to normal as quickly as possible,” said Billy Tauzin, president and CEO of PhRMA in a prepared statement.

http://pharmtech.findpharma.com

Tag Cloud